Annual Operating Profit
-$378.50 M
-$10.46 M-2.84%
December 31, 2022
Summary
- As of March 1, 2025, SRNE annual operating income is -$378.50 million, with the most recent change of -$10.46 million (-2.84%) on December 31, 2022.
- During the last 3 years, SRNE annual operating profit has fallen by -$183.32 million (-93.92%).
- SRNE annual operating profit is now -835.85% below its all-time high of $51.44 million, reached on December 31, 2017.
Performance
SRNE Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Operating Profit
-$76.77 M
+$12.08 M+13.60%
June 30, 2023
Summary
- As of March 1, 2025, SRNE quarterly operating income is -$76.77 million, with the most recent change of +$12.08 million (+13.60%) on June 30, 2023.
- Over the past year, SRNE quarterly operating profit has increased by +$12.08 million (+13.60%).
- SRNE quarterly operating profit is now -182.23% below its all-time high of $93.35 million, reached on September 30, 2017.
Performance
SRNE Quarterly Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM Operating Profit
-$355.52 M
+$15.11 M+4.08%
June 30, 2023
Summary
- As of March 1, 2025, SRNE TTM operating income is -$355.52 million, with the most recent change of +$15.11 million (+4.08%) on June 30, 2023.
- Over the past year, SRNE TTM operating profit has increased by +$15.11 million (+4.08%).
- SRNE TTM operating profit is now -749.88% below its all-time high of $54.71 million, reached on March 31, 2018.
Performance
SRNE TTM Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Operating Profit Formula
Operating Profit = Gross Profit − Operating Expenses
SRNE Operating Profit Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -2.8% | +13.6% | +4.1% |
| 3 y3 years | -93.9% | +13.6% | +4.1% |
| 5 y5 years | -835.9% | +13.6% | +4.1% |
SRNE Operating Profit Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -2.8% | at low | at high | +30.3% | at high | +11.9% |
| 5 y | 5-year | -93.9% | at low | -79.2% | +30.3% | -99.8% | +11.9% |
| alltime | all time | -835.9% | at low | -182.2% | +30.3% | -749.9% | +11.9% |
Sorrento Therapeutics Operating Profit History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2023 | - | -$76.77 M(-13.6%) | -$355.52 M(-4.1%) |
| Mar 2023 | - | -$88.85 M(+11.4%) | -$370.64 M(-2.1%) |
| Dec 2022 | -$378.50 M(+2.8%) | -$79.77 M(-27.6%) | -$378.50 M(-6.2%) |
| Sep 2022 | - | -$110.14 M(+19.9%) | -$403.65 M(+5.2%) |
| Jun 2022 | - | -$91.88 M(-5.0%) | -$383.76 M(-0.9%) |
| Mar 2022 | - | -$96.71 M(-7.8%) | -$387.36 M(+5.2%) |
| Dec 2021 | -$368.05 M(+82.6%) | -$104.91 M(+16.2%) | -$368.05 M(+11.4%) |
| Sep 2021 | - | -$90.26 M(-5.5%) | -$330.43 M(+14.6%) |
| Jun 2021 | - | -$95.48 M(+23.4%) | -$288.39 M(+22.3%) |
| Mar 2021 | - | -$77.39 M(+15.0%) | -$235.76 M(+17.0%) |
| Dec 2020 | -$201.53 M(+3.3%) | -$67.30 M(+39.6%) | -$201.53 M(+13.3%) |
| Sep 2020 | - | -$48.22 M(+12.5%) | -$177.90 M(-2.8%) |
| Jun 2020 | - | -$42.85 M(-0.7%) | -$182.96 M(-3.9%) |
| Mar 2020 | - | -$43.16 M(-1.2%) | -$190.48 M(-2.4%) |
| Dec 2019 | -$195.18 M(+50.7%) | -$43.67 M(-18.0%) | -$195.18 M(-0.1%) |
| Sep 2019 | - | -$53.28 M(+5.8%) | -$195.34 M(+8.2%) |
| Jun 2019 | - | -$50.36 M(+5.2%) | -$180.45 M(+14.9%) |
| Mar 2019 | - | -$47.87 M(+9.2%) | -$157.03 M(+21.3%) |
| Dec 2018 | -$129.48 M(-351.7%) | -$43.83 M(+14.1%) | -$129.48 M(+49.0%) |
| Sep 2018 | - | -$38.40 M(+42.6%) | -$86.89 M(-293.7%) |
| Jun 2018 | - | -$26.93 M(+32.5%) | $44.86 M(-18.0%) |
| Mar 2018 | - | -$20.32 M(+1541.4%) | $54.71 M(+6.4%) |
| Dec 2017 | $51.44 M(-185.9%) | -$1.24 M(-101.3%) | $51.44 M(+56.2%) |
| Sep 2017 | - | $93.35 M(-646.3%) | $32.94 M(-144.3%) |
| Jun 2017 | - | -$17.09 M(-27.6%) | -$74.35 M(+3.7%) |
| Mar 2017 | - | -$23.59 M(+19.5%) | -$71.73 M(+19.8%) |
| Dec 2016 | -$59.90 M(+19.8%) | -$19.74 M(+41.6%) | -$59.90 M(+3.5%) |
| Sep 2016 | - | -$13.94 M(-3.7%) | -$57.87 M(+4.3%) |
| Jun 2016 | - | -$14.47 M(+23.1%) | -$55.50 M(+7.6%) |
| Mar 2016 | - | -$11.75 M(-33.6%) | -$51.57 M(+3.2%) |
| Dec 2015 | -$49.99 M | -$17.71 M(+53.2%) | -$49.99 M(+19.0%) |
| Sep 2015 | - | -$11.57 M(+9.8%) | -$42.02 M(+11.8%) |
| Jun 2015 | - | -$10.53 M(+3.5%) | -$37.59 M(+7.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2015 | - | -$10.18 M(+4.4%) | -$35.05 M(+1.5%) |
| Dec 2014 | -$34.53 M(+120.2%) | -$9.75 M(+36.7%) | -$34.53 M(+10.9%) |
| Sep 2014 | - | -$7.13 M(-10.8%) | -$31.14 M(+14.0%) |
| Jun 2014 | - | -$7.99 M(-17.3%) | -$27.32 M(+19.6%) |
| Mar 2014 | - | -$9.66 M(+52.1%) | -$22.83 M(+45.6%) |
| Dec 2013 | -$15.68 M(+223.2%) | -$6.35 M(+92.1%) | -$15.68 M(+41.5%) |
| Sep 2013 | - | -$3.31 M(-5.7%) | -$11.08 M(+22.9%) |
| Jun 2013 | - | -$3.51 M(+39.5%) | -$9.02 M(+39.7%) |
| Mar 2013 | - | -$2.51 M(+43.1%) | -$6.46 M(+33.1%) |
| Dec 2012 | -$4.85 M(+49.6%) | -$1.76 M(+41.3%) | -$4.85 M(+25.7%) |
| Sep 2012 | - | -$1.24 M(+31.6%) | -$3.86 M(+16.3%) |
| Jun 2012 | - | -$944.90 K(+4.1%) | -$3.32 M(-4.2%) |
| Mar 2012 | - | -$907.60 K(+18.9%) | -$3.46 M(+6.8%) |
| Dec 2011 | -$3.24 M(+78.9%) | -$763.30 K(+8.5%) | -$3.24 M(+21.5%) |
| Sep 2011 | - | -$703.70 K(-35.4%) | -$2.67 M(+10.7%) |
| Jun 2011 | - | -$1.09 M(+58.8%) | -$2.41 M(+27.0%) |
| Mar 2011 | - | -$686.10 K(+263.6%) | -$1.90 M(+4.7%) |
| Dec 2010 | -$1.81 M(+89.9%) | -$188.70 K(-57.6%) | -$1.81 M(-21.7%) |
| Sep 2010 | - | -$445.50 K(-22.7%) | -$2.31 M(+9.8%) |
| Jun 2010 | - | -$576.50 K(-4.1%) | -$2.11 M(+35.4%) |
| Mar 2010 | - | -$601.40 K(-12.8%) | -$1.56 M(+63.0%) |
| Dec 2009 | -$954.10 K(+3612.5%) | -$689.90 K(+189.0%) | -$954.20 K(+555.4%) |
| Sep 2009 | - | -$238.70 K(+832.4%) | -$145.60 K(+345.3%) |
| Jun 2009 | - | -$25.60 K(-121.6%) | -$32.70 K(+27.2%) |
| Dec 2008 | -$25.70 K(-89.3%) | $118.70 K(-194.4%) | -$25.70 K(-83.1%) |
| Sep 2008 | - | -$125.80 K(+2229.6%) | -$151.80 K(+314.8%) |
| Jun 2008 | - | -$5400.00(-59.1%) | -$36.60 K(-16.4%) |
| Mar 2008 | - | -$13.20 K(+78.4%) | -$43.80 K(-81.8%) |
| Dec 2007 | -$240.60 K(-45.2%) | -$7400.00(-30.2%) | -$240.50 K(+3.2%) |
| Sep 2007 | - | -$10.60 K(-15.9%) | -$233.10 K(+4.8%) |
| Jun 2007 | - | -$12.60 K(-94.0%) | -$222.50 K(+6.0%) |
| Mar 2007 | - | -$209.90 K | -$209.90 K |
| Dec 2006 | -$439.30 K | - | - |
FAQ
- What is Sorrento Therapeutics annual operating income?
- What is the all time high annual operating profit for Sorrento Therapeutics?
- What is Sorrento Therapeutics annual operating profit year-on-year change?
- What is Sorrento Therapeutics quarterly operating income?
- What is the all time high quarterly operating profit for Sorrento Therapeutics?
- What is Sorrento Therapeutics quarterly operating profit year-on-year change?
- What is Sorrento Therapeutics TTM operating income?
- What is the all time high TTM operating profit for Sorrento Therapeutics?
- What is Sorrento Therapeutics TTM operating profit year-on-year change?
What is Sorrento Therapeutics annual operating income?
The current annual operating profit of SRNE is -$378.50 M
What is the all time high annual operating profit for Sorrento Therapeutics?
Sorrento Therapeutics all-time high annual operating income is $51.44 M
What is Sorrento Therapeutics annual operating profit year-on-year change?
Over the past year, SRNE annual operating income has changed by -$10.46 M (-2.84%)
What is Sorrento Therapeutics quarterly operating income?
The current quarterly operating profit of SRNE is -$76.77 M
What is the all time high quarterly operating profit for Sorrento Therapeutics?
Sorrento Therapeutics all-time high quarterly operating income is $93.35 M
What is Sorrento Therapeutics quarterly operating profit year-on-year change?
Over the past year, SRNE quarterly operating income has changed by +$12.08 M (+13.60%)
What is Sorrento Therapeutics TTM operating income?
The current TTM operating profit of SRNE is -$355.52 M
What is the all time high TTM operating profit for Sorrento Therapeutics?
Sorrento Therapeutics all-time high TTM operating income is $54.71 M
What is Sorrento Therapeutics TTM operating profit year-on-year change?
Over the past year, SRNE TTM operating income has changed by +$15.11 M (+4.08%)